Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213745 | 1.00 | GAA (0.53) | GAARAB9ANPC1LMNATP53 | |
| SCHEMBL13686121 | 1.00 | GAA (0.53) | GAARAB9ANPC1LMNATP53 | |
| SCHEMBL3346077 | 0.99 | GAA (0.51) | GAARAB9ANPC1LMNATP53 | |
| SCHEMBL11936601 | 0.87 | MEN1 (0.38) | GAARAB9ANPC1LMNATP53 | |
| SCHEMBL727965 | 0.87 | PRMT1 (0.53) | PRMT1F2ST14PLAUPLG | |
| Hydrochloric Acid SCHEMBL3241146 | 0.86 | PRSS1 (0.54) | PRMT1F2ST14PLAUPLG | |
| SCHEMBL3192337 | 0.86 | PRSS1 (0.52) | PRMT1F2ST14PLAUPLG | |
| SCHEMBL3262577 | 0.82 | MEN1 (0.39) | GAAMEN1KMT2APRMT1F2 | |
| SCHEMBL12213750 | 0.82 | CYP19A1 (0.45) | RAB9ALMNAMAPTMEN1KMT2A | |
| SCHEMBL3842184 | 0.81 | ALDH1A1 (0.44) | GAAMAPTMEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861601-B2 | Treatment of pulmonary arterial hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-07-07 | — | — | US | disclosed |
| US-9233089-B2 | Treatment of pulmonary hypertension with leukotriene inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2827849-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013142369-A1 | TREATMENT OF PULMONARY HYPERTENSION WITH LEUKOTRIENE INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-26 | — | — | US | disclosed |
| EP-2146974-A1 | N- HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY]PENTOXY} BENZAMIDINE 2 ETHANSULFONIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dong Wha Pharmaceutical Co., Ltd. (KR) | 2010-01-27 | — | — | EP | disclosed |
| EP-1773794-A4 | AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE | DONG WHA PHARM IND CO LTD (KR) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008130172-A1 | N- HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY]PENTOXY} BENZAMIDINE 2 ETHANSULFONIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG WHA PHARMACEUTICAL CO. LTD. (KR) | 2008-10-30 | — | — | WO | disclosed |
| EP-1701722-A4 | N-HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY¨]PENTOXY}BENZAMIDINE 2 METHANSULFONIC ACID SALT | DONG WHA PHARM IND CO LTD (KR) | 2007-05-16 | — | — | EP | disclosed |
| EP-1773333-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALLERGIC INFLAMMATORY DISEASE | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1773794-A1 | AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2007-04-18 | — | — | EP | disclosed |
| EP-1701722-A1 | N-HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY¨]PENTOXY}BENZAMIDINE 2 METHANSULFONIC ACID SALT | Dong Wha Pharmaceutical. Ind. Co., Ltd. (KR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2006057501-A1 | N-HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY]PENTOXY}BENZAMIDINE 2 METHANSULFONIC ACID SALT | DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006004370-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALLERGIC INFLAMMATORY DISEASE | DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004368-A1 | AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE | DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251787-A1 | Treatment of Pulmonary Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | GAA 3902/4885RAB9A 4158/4885NPC1 3509/4885 |
| US-20160193168-A1 | Treatment of Pulmonary Arterial Hypertension with Leukotriene Inhibitors | LTA4H, LTB4R2, LTB4R | GAA 4096/4885RAB9A 4126/4885NPC1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.